Aurinia Pharmaceuticals (AUPH) Competitors

$15.45 -0.45 (-2.83%)

Closing price 04:00 PM Eastern

Extended Trading

$15.44 0.00 (-0.03%)

As of 04:12 PM Eastern

AUPH vs. PCVX, QGEN, KYMR, PTGX, and SYRE

Should you buy Aurinia Pharmaceuticals stock or one of its competitors? MarketBeat compares Aurinia Pharmaceuticals with other companies and stocks that may be similar based on industry, sector, market capitalization, business model, investor interest, or shared news coverage. Companies and stocks commonly compared with Aurinia Pharmaceuticals include Vaxcyte (PCVX), Qiagen (QGEN), Kymera Therapeutics (KYMR), Protagonist Therapeutics (PTGX), and Spyre Therapeutics (SYRE). These companies are all part of the "pharmaceutical products" industry.

How does Aurinia Pharmaceuticals compare to Vaxcyte?

Vaxcyte (NASDAQ:PCVX) and Aurinia Pharmaceuticals (NASDAQ:AUPH) are both medical companies, but which is the better business? We will compare the two businesses based on the strength of their institutional ownership, profitability, valuation, analyst recommendations, media sentiment, earnings, risk and dividends.

Vaxcyte presently has a consensus target price of $86.00, suggesting a potential upside of 81.47%. Aurinia Pharmaceuticals has a consensus target price of $17.25, suggesting a potential upside of 11.65%. Given Vaxcyte's stronger consensus rating and higher possible upside, equities research analysts clearly believe Vaxcyte is more favorable than Aurinia Pharmaceuticals.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Vaxcyte	1 Sell rating(s)	1 Hold rating(s)	6 Buy rating(s)	0 Strong Buy rating(s)	2.63
Aurinia Pharmaceuticals	0 Sell rating(s)	4 Hold rating(s)	2 Buy rating(s)	0 Strong Buy rating(s)	2.33

In the previous week, Vaxcyte had 2 more articles in the media than Aurinia Pharmaceuticals. MarketBeat recorded 4 mentions for Vaxcyte and 2 mentions for Aurinia Pharmaceuticals. Vaxcyte's average media sentiment score of 0.49 beat Aurinia Pharmaceuticals' score of 0.11 indicating that Vaxcyte is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Vaxcyte	1 Very Positive mention(s)	0 Positive mention(s)	3 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral
Aurinia Pharmaceuticals	1 Very Positive mention(s)	0 Positive mention(s)	0 Neutral mention(s)	1 Negative mention(s)	0 Very Negative mention(s)	Neutral

96.8% of Vaxcyte shares are held by institutional investors. Comparatively, 36.8% of Aurinia Pharmaceuticals shares are held by institutional investors. 3.1% of Vaxcyte shares are held by insiders. Comparatively, 12.2% of Aurinia Pharmaceuticals shares are held by insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a stock is poised for long-term growth.

Aurinia Pharmaceuticals has a net margin of 99.97% compared to Vaxcyte's net margin of 0.00%. Aurinia Pharmaceuticals' return on equity of 26.62% beat Vaxcyte's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Vaxcyte	N/A	-32.51%	-29.51%
Aurinia Pharmaceuticals	99.97%	26.62%	19.65%

Vaxcyte has a beta of 1.3, indicating that its stock price is 30% more volatile than the broader market. Comparatively, Aurinia Pharmaceuticals has a beta of 1.44, indicating that its stock price is 44% more volatile than the broader market.

Aurinia Pharmaceuticals has higher revenue and earnings than Vaxcyte. Vaxcyte is trading at a lower price-to-earnings ratio than Aurinia Pharmaceuticals, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Vaxcyte	N/A	N/A	-$766.63M	-$6.88	N/A
Aurinia Pharmaceuticals	$283.05M	7.02	$287.20M	$2.17	7.12

Summary

Aurinia Pharmaceuticals beats Vaxcyte on 9 of the 15 factors compared between the two stocks.

How does Aurinia Pharmaceuticals compare to Qiagen?

Qiagen (NYSE:QGEN) and Aurinia Pharmaceuticals (NASDAQ:AUPH) are both medical companies, but which is the better business? We will contrast the two companies based on the strength of their media sentiment, institutional ownership, risk, earnings, profitability, dividends, valuation and analyst recommendations.

Qiagen has higher revenue and earnings than Aurinia Pharmaceuticals. Aurinia Pharmaceuticals is trading at a lower price-to-earnings ratio than Qiagen, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Qiagen	$2.09B	3.44	$424.88M	$1.91	18.26
Aurinia Pharmaceuticals	$283.05M	7.02	$287.20M	$2.17	7.12

Qiagen has a beta of 0.64, indicating that its stock price is 36% less volatile than the broader market. Comparatively, Aurinia Pharmaceuticals has a beta of 1.44, indicating that its stock price is 44% more volatile than the broader market.

70.0% of Qiagen shares are owned by institutional investors. Comparatively, 36.8% of Aurinia Pharmaceuticals shares are owned by institutional investors. 9.0% of Qiagen shares are owned by company insiders. Comparatively, 12.2% of Aurinia Pharmaceuticals shares are owned by company insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a company is poised for long-term growth.

In the previous week, Qiagen had 9 more articles in the media than Aurinia Pharmaceuticals. MarketBeat recorded 11 mentions for Qiagen and 2 mentions for Aurinia Pharmaceuticals. Aurinia Pharmaceuticals' average media sentiment score of 0.11 beat Qiagen's score of 0.03 indicating that Aurinia Pharmaceuticals is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Qiagen	0 Very Positive mention(s)	0 Positive mention(s)	11 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral
Aurinia Pharmaceuticals	1 Very Positive mention(s)	0 Positive mention(s)	0 Neutral mention(s)	1 Negative mention(s)	0 Very Negative mention(s)	Neutral

Aurinia Pharmaceuticals has a net margin of 99.97% compared to Qiagen's net margin of 19.16%. Aurinia Pharmaceuticals' return on equity of 26.62% beat Qiagen's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Qiagen	19.16%	14.40%	8.40%
Aurinia Pharmaceuticals	99.97%	26.62%	19.65%

Qiagen presently has a consensus target price of $44.98, indicating a potential upside of 28.94%. Aurinia Pharmaceuticals has a consensus target price of $17.25, indicating a potential upside of 11.65%. Given Qiagen's stronger consensus rating and higher probable upside, analysts plainly believe Qiagen is more favorable than Aurinia Pharmaceuticals.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Qiagen	0 Sell rating(s)	7 Hold rating(s)	4 Buy rating(s)	1 Strong Buy rating(s)	2.50
Aurinia Pharmaceuticals	0 Sell rating(s)	4 Hold rating(s)	2 Buy rating(s)	0 Strong Buy rating(s)	2.33

Summary

Qiagen beats Aurinia Pharmaceuticals on 9 of the 17 factors compared between the two stocks.

How does Aurinia Pharmaceuticals compare to Kymera Therapeutics?

Kymera Therapeutics (NASDAQ:KYMR) and Aurinia Pharmaceuticals (NASDAQ:AUPH) are both medical companies, but which is the superior investment? We will contrast the two businesses based on the strength of their earnings, valuation, institutional ownership, risk, profitability, dividends, analyst recommendations and media sentiment.

In the previous week, Kymera Therapeutics had 2 more articles in the media than Aurinia Pharmaceuticals. MarketBeat recorded 4 mentions for Kymera Therapeutics and 2 mentions for Aurinia Pharmaceuticals. Kymera Therapeutics' average media sentiment score of 0.42 beat Aurinia Pharmaceuticals' score of 0.11 indicating that Kymera Therapeutics is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Kymera Therapeutics	1 Very Positive mention(s)	0 Positive mention(s)	3 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral
Aurinia Pharmaceuticals	1 Very Positive mention(s)	0 Positive mention(s)	0 Neutral mention(s)	1 Negative mention(s)	0 Very Negative mention(s)	Neutral

Aurinia Pharmaceuticals has higher revenue and earnings than Kymera Therapeutics. Kymera Therapeutics is trading at a lower price-to-earnings ratio than Aurinia Pharmaceuticals, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Kymera Therapeutics	$39.21M	169.11	-$311.35M	-$3.57	N/A
Aurinia Pharmaceuticals	$283.05M	7.02	$287.20M	$2.17	7.12

Kymera Therapeutics presently has a consensus price target of $118.10, indicating a potential upside of 46.50%. Aurinia Pharmaceuticals has a consensus price target of $17.25, indicating a potential upside of 11.65%. Given Kymera Therapeutics' stronger consensus rating and higher probable upside, analysts plainly believe Kymera Therapeutics is more favorable than Aurinia Pharmaceuticals.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Kymera Therapeutics	1 Sell rating(s)	0 Hold rating(s)	20 Buy rating(s)	1 Strong Buy rating(s)	2.95
Aurinia Pharmaceuticals	0 Sell rating(s)	4 Hold rating(s)	2 Buy rating(s)	0 Strong Buy rating(s)	2.33

36.8% of Aurinia Pharmaceuticals shares are owned by institutional investors. 16.0% of Kymera Therapeutics shares are owned by insiders. Comparatively, 12.2% of Aurinia Pharmaceuticals shares are owned by insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a company will outperform the market over the long term.

Aurinia Pharmaceuticals has a net margin of 99.97% compared to Kymera Therapeutics' net margin of -611.94%. Aurinia Pharmaceuticals' return on equity of 26.62% beat Kymera Therapeutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Kymera Therapeutics	-611.94%	-24.71%	-22.05%
Aurinia Pharmaceuticals	99.97%	26.62%	19.65%

Kymera Therapeutics has a beta of 2.06, suggesting that its stock price is 106% more volatile than the broader market. Comparatively, Aurinia Pharmaceuticals has a beta of 1.44, suggesting that its stock price is 44% more volatile than the broader market.

Summary

Kymera Therapeutics beats Aurinia Pharmaceuticals on 9 of the 17 factors compared between the two stocks.

How does Aurinia Pharmaceuticals compare to Protagonist Therapeutics?

Protagonist Therapeutics (NASDAQ:PTGX) and Aurinia Pharmaceuticals (NASDAQ:AUPH) are both medical companies, but which is the superior stock? We will contrast the two companies based on the strength of their earnings, risk, profitability, dividends, valuation, media sentiment, analyst recommendations and institutional ownership.

Protagonist Therapeutics currently has a consensus target price of $115.21, suggesting a potential upside of 12.94%. Aurinia Pharmaceuticals has a consensus target price of $17.25, suggesting a potential upside of 11.65%. Given Protagonist Therapeutics' stronger consensus rating and higher possible upside, equities research analysts plainly believe Protagonist Therapeutics is more favorable than Aurinia Pharmaceuticals.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Protagonist Therapeutics	1 Sell rating(s)	1 Hold rating(s)	14 Buy rating(s)	0 Strong Buy rating(s)	2.81
Aurinia Pharmaceuticals	0 Sell rating(s)	4 Hold rating(s)	2 Buy rating(s)	0 Strong Buy rating(s)	2.33

98.6% of Protagonist Therapeutics shares are owned by institutional investors. Comparatively, 36.8% of Aurinia Pharmaceuticals shares are owned by institutional investors. 5.2% of Protagonist Therapeutics shares are owned by company insiders. Comparatively, 12.2% of Aurinia Pharmaceuticals shares are owned by company insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a stock is poised for long-term growth.

Protagonist Therapeutics has a beta of 1.89, indicating that its stock price is 89% more volatile than the broader market. Comparatively, Aurinia Pharmaceuticals has a beta of 1.44, indicating that its stock price is 44% more volatile than the broader market.

Aurinia Pharmaceuticals has higher revenue and earnings than Protagonist Therapeutics. Protagonist Therapeutics is trading at a lower price-to-earnings ratio than Aurinia Pharmaceuticals, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Protagonist Therapeutics	$46.02M	142.55	-$130.15M	-$1.81	N/A
Aurinia Pharmaceuticals	$283.05M	7.02	$287.20M	$2.17	7.12

Aurinia Pharmaceuticals has a net margin of 99.97% compared to Protagonist Therapeutics' net margin of -154.88%. Aurinia Pharmaceuticals' return on equity of 26.62% beat Protagonist Therapeutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Protagonist Therapeutics	-154.88%	-17.76%	-16.47%
Aurinia Pharmaceuticals	99.97%	26.62%	19.65%

In the previous week, Protagonist Therapeutics had 7 more articles in the media than Aurinia Pharmaceuticals. MarketBeat recorded 9 mentions for Protagonist Therapeutics and 2 mentions for Aurinia Pharmaceuticals. Protagonist Therapeutics' average media sentiment score of 0.76 beat Aurinia Pharmaceuticals' score of 0.11 indicating that Protagonist Therapeutics is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Protagonist Therapeutics	4 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Aurinia Pharmaceuticals	1 Very Positive mention(s)	0 Positive mention(s)	0 Neutral mention(s)	1 Negative mention(s)	0 Very Negative mention(s)	Neutral

Summary

Protagonist Therapeutics and Aurinia Pharmaceuticals tied by winning 8 of the 16 factors compared between the two stocks.

How does Aurinia Pharmaceuticals compare to Spyre Therapeutics?

Aurinia Pharmaceuticals (NASDAQ:AUPH) and Spyre Therapeutics (NASDAQ:SYRE) are both medical companies, but which is the superior stock? We will compare the two companies based on the strength of their earnings, analyst recommendations, media sentiment, institutional ownership, risk, valuation, profitability and dividends.

Aurinia Pharmaceuticals has a beta of 1.44, meaning that its share price is 44% more volatile than the broader market. Comparatively, Spyre Therapeutics has a beta of 3.12, meaning that its share price is 212% more volatile than the broader market.

Aurinia Pharmaceuticals has a net margin of 99.97% compared to Spyre Therapeutics' net margin of 0.00%. Aurinia Pharmaceuticals' return on equity of 26.62% beat Spyre Therapeutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Aurinia Pharmaceuticals	99.97%	26.62%	19.65%
Spyre Therapeutics	N/A	-42.88%	-27.76%

Aurinia Pharmaceuticals presently has a consensus price target of $17.25, indicating a potential upside of 11.65%. Spyre Therapeutics has a consensus price target of $90.25, indicating a potential upside of 21.43%. Given Spyre Therapeutics' stronger consensus rating and higher possible upside, analysts plainly believe Spyre Therapeutics is more favorable than Aurinia Pharmaceuticals.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Aurinia Pharmaceuticals	0 Sell rating(s)	4 Hold rating(s)	2 Buy rating(s)	0 Strong Buy rating(s)	2.33
Spyre Therapeutics	1 Sell rating(s)	0 Hold rating(s)	10 Buy rating(s)	2 Strong Buy rating(s)	3.00

In the previous week, Aurinia Pharmaceuticals and Aurinia Pharmaceuticals both had 2 articles in the media. Spyre Therapeutics' average media sentiment score of 0.86 beat Aurinia Pharmaceuticals' score of 0.11 indicating that Spyre Therapeutics is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Aurinia Pharmaceuticals	1 Very Positive mention(s)	0 Positive mention(s)	0 Neutral mention(s)	1 Negative mention(s)	0 Very Negative mention(s)	Neutral
Spyre Therapeutics	1 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

Aurinia Pharmaceuticals has higher revenue and earnings than Spyre Therapeutics. Spyre Therapeutics is trading at a lower price-to-earnings ratio than Aurinia Pharmaceuticals, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Aurinia Pharmaceuticals	$283.05M	7.02	$287.20M	$2.17	7.12
Spyre Therapeutics	$890K	7,251.63	-$155.20M	-$2.08	N/A

36.8% of Aurinia Pharmaceuticals shares are owned by institutional investors. Comparatively, 80.4% of Spyre Therapeutics shares are owned by institutional investors. 12.2% of Aurinia Pharmaceuticals shares are owned by insiders. Comparatively, 15.7% of Spyre Therapeutics shares are owned by insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a stock is poised for long-term growth.

Summary

Spyre Therapeutics beats Aurinia Pharmaceuticals on 9 of the 16 factors compared between the two stocks.

Get Aurinia Pharmaceuticals News Delivered to You Automatically

Subscribe Now

SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding AUPH and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.

AUPH vs. The Competition

Export

Metric	Aurinia Pharmaceuticals	MED Industry	Medical Sector	NASDAQ Exchange
Market Cap	$1.99B	$3.02B	$6.34B	$12.29B
Dividend Yield	N/A	1.97%	2.80%	5.36%
P/E Ratio	7.12	17.78	20.92	25.47
Price / Sales	7.02	253.28	521.15	73.36
Price / Cash	15.35	56.99	43.18	55.00
Price / Book	3.50	4.58	9.98	7.00
Net Income	$287.20M	$74.99M	$3.55B	$335.16M
7 Day Performance	-2.46%	-2.38%	0.40%	-0.29%
1 Month Performance	-2.34%	-4.15%	-0.02%	1.18%
1 Year Performance	85.25%	36.30%	34.94%	34.78%

Aurinia Pharmaceuticals Competitors List

Export

Company	MarketRank	Share Price	Analysts' Price Target	1Y Price Performance	Market Cap	Revenue	P/E Ratio	Employee Count	Indicator(s)
AUPH Aurinia Pharmaceuticals	2.4759 of 5 stars	$15.45 -2.8%	$17.25 +11.7%	+91.6%	$1.99B	$283.05M	7.12	300
PCVX Vaxcyte	2.8937 of 5 stars	$48.44 -7.5%	$86.00 +77.5%	+29.0%	$7.56B	N/A	N/A	160
QGEN Qiagen	4.5533 of 5 stars	$33.78 +2.4%	$44.98 +33.2%	-22.0%	$6.80B	$2.09B	17.64	5,654	Analyst Forecast
KYMR Kymera Therapeutics	2.2531 of 5 stars	$79.67 -3.1%	$118.10 +48.2%	+156.5%	$6.76B	$39.21M	N/A	170
PTGX Protagonist Therapeutics	2.4263 of 5 stars	$100.74 -1.4%	$113.69 +12.9%	+116.4%	$6.57B	$46.02M	N/A	120	Analyst Forecast Analyst Revision

Related Companies and Tools

Related Companies

Top 10 Stock Comparisons

This page (NASDAQ:AUPH) was last updated on 5/21/2026 by MarketBeat.com Staff.

From Our Partners

Get 30 Days of MarketBeat All Access for Free

Start Your 30-Day Trial

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Aurinia Pharmaceuticals (AUPH) Competitors

AUPH vs. PCVX, QGEN, KYMR, PTGX, and SYRE

How does Aurinia Pharmaceuticals compare to Vaxcyte?

Summary

How does Aurinia Pharmaceuticals compare to Qiagen?

Summary

How does Aurinia Pharmaceuticals compare to Kymera Therapeutics?

Summary

How does Aurinia Pharmaceuticals compare to Protagonist Therapeutics?

Summary

How does Aurinia Pharmaceuticals compare to Spyre Therapeutics?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

AUPH vs. The Competition

Aurinia Pharmaceuticals Competitors List

Related Companies and Tools

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

Aurinia Pharmaceuticals (AUPH) Competitors

AUPH vs. PCVX, QGEN, KYMR, PTGX, and SYRE

How does Aurinia Pharmaceuticals compare to Vaxcyte?

Do analysts prefer PCVX or AUPH?

Does the media favor PCVX or AUPH?

Do insiders & institutionals have more ownership in PCVX or AUPH?

Is PCVX or AUPH more profitable?

Which has more volatility & risk, PCVX or AUPH?

Which has higher valuation & earnings, PCVX or AUPH?

Summary

How does Aurinia Pharmaceuticals compare to Qiagen?

Which has higher earnings and valuation, QGEN or AUPH?

Which has more volatility & risk, QGEN or AUPH?

Do insiders & institutionals have more ownership in QGEN or AUPH?

Does the media favor QGEN or AUPH?

Is QGEN or AUPH more profitable?

Do analysts rate QGEN or AUPH?

Summary

How does Aurinia Pharmaceuticals compare to Kymera Therapeutics?

Does the media refer more to KYMR or AUPH?

Which has stronger earnings and valuation, KYMR or AUPH?

Do analysts rate KYMR or AUPH?

Do insiders and institutionals have more ownership in KYMR or AUPH?

Is KYMR or AUPH more profitable?

Which has more volatility and risk, KYMR or AUPH?

Summary

How does Aurinia Pharmaceuticals compare to Protagonist Therapeutics?

Do analysts rate PTGX or AUPH?

Do institutionals and insiders hold more shares of PTGX or AUPH?

Which has more volatility & risk, PTGX or AUPH?

Which has preferable valuation & earnings, PTGX or AUPH?

Is PTGX or AUPH more profitable?

Does the media favor PTGX or AUPH?

Summary

How does Aurinia Pharmaceuticals compare to Spyre Therapeutics?

Which has more risk & volatility, AUPH or SYRE?

Is AUPH or SYRE more profitable?

Do analysts recommend AUPH or SYRE?

Does the media prefer AUPH or SYRE?

Which has preferable earnings & valuation, AUPH or SYRE?

Do insiders & institutionals believe in AUPH or SYRE?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

AUPH vs. The Competition

Aurinia Pharmaceuticals Competitors List

Related Companies and Tools

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools